Literature DB >> 22913595

Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology.

Peixuan Guo1, Farzin Haque, Brent Hallahan, Randall Reif, Hui Li.   

Abstract

The field of RNA nanotechnology is rapidly emerging. RNA can be manipulated with the simplicity characteristic of DNA to produce nanoparticles with a diversity of quaternary structures by self-assembly. Additionally RNA is tremendously versatile in its function and some RNA molecules display catalytic activities much like proteins. Thus, RNA has the advantage of both worlds. However, the instability of RNA has made many scientists flinch away from RNA nanotechnology. Other concerns that have deterred the progress of RNA therapeutics include the induction of interferons, stimulation of cytokines, and activation of other immune systems, as well as short pharmacokinetic profiles in vivo. This review will provide some solutions and perspectives on the chemical and thermodynamic stability, in vivo half-life and biodistribution, yield and production cost, in vivo toxicity and side effect, specific delivery and targeting, as well as endosomal trapping and escape.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22913595      PMCID: PMC3426230          DOI: 10.1089/nat.2012.0350

Source DB:  PubMed          Journal:  Nucleic Acid Ther        ISSN: 2159-3337            Impact factor:   5.486


  168 in total

Review 1.  MicroRNAs: small RNAs with a big role in gene regulation.

Authors:  Lin He; Gregory J Hannon
Journal:  Nat Rev Genet       Date:  2004-07       Impact factor: 53.242

2.  Bottom-up Assembly of RNA Arrays and Superstructures as Potential Parts in Nanotechnology.

Authors:  Dan Shu; Wulf-Dieter Moll; Zhaoxiang Deng; Chengde Mao; Peixuan Guo
Journal:  Nano Lett       Date:  2004-09       Impact factor: 11.189

Review 3.  RNA nanotechnology: engineering, assembly and applications in detection, gene delivery and therapy.

Authors:  Peixuan Guo
Journal:  J Nanosci Nanotechnol       Date:  2005-12

4.  A generic protocol for the expression and purification of recombinant RNA in Escherichia coli using a tRNA scaffold.

Authors:  Luc Ponchon; Geneviève Beauvais; Sylvie Nonin-Lecomte; Frédéric Dardel
Journal:  Nat Protoc       Date:  2009-05-28       Impact factor: 13.491

5.  Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.

Authors:  James O McNamara; Eran R Andrechek; Yong Wang; Kristi D Viles; Rachel E Rempel; Eli Gilboa; Bruce A Sullenger; Paloma H Giangrande
Journal:  Nat Biotechnol       Date:  2006-06-25       Impact factor: 54.908

6.  Before and after endosomal escape: roles of stimuli-converting siRNA/polymer interactions in determining gene silencing efficiency.

Authors:  Young Jik Kwon
Journal:  Acc Chem Res       Date:  2011-11-21       Impact factor: 22.384

7.  Construction of folate-conjugated pRNA of bacteriophage phi29 DNA packaging motor for delivery of chimeric siRNA to nasopharyngeal carcinoma cells.

Authors:  S Guo; F Huang; P Guo
Journal:  Gene Ther       Date:  2006-05       Impact factor: 5.250

8.  Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.

Authors:  Jiehua Zhou; Haitang Li; Shirley Li; John Zaia; John J Rossi
Journal:  Mol Ther       Date:  2008-05-06       Impact factor: 11.454

9.  Targeted delivery of anti-coxsackievirus siRNAs using ligand-conjugated packaging RNAs.

Authors:  Huifang M Zhang; Yue Su; Songchuan Guo; Ji Yuan; Travis Lim; Jing Liu; Peixuan Guo; Decheng Yang
Journal:  Antiviral Res       Date:  2009-07-16       Impact factor: 5.970

Review 10.  Interfering with disease: a progress report on siRNA-based therapeutics.

Authors:  Antonin de Fougerolles; Hans-Peter Vornlocher; John Maraganore; Judy Lieberman
Journal:  Nat Rev Drug Discov       Date:  2007-06       Impact factor: 84.694

View more
  50 in total

1.  Computational selection and experimental validation of allosteric ribozymes that sense a specific sequence of human telomerase reverse transcriptase mRNAs as universal anticancer therapy agents.

Authors:  Robert Penchovsky; Gergana T Kostova
Journal:  Nucleic Acid Ther       Date:  2013-11-09       Impact factor: 5.486

2.  RNAi-microsponges form through self-assembly of the organic and inorganic products of transcription.

Authors:  Kevin E Shopsowitz; Young Hoon Roh; Zhou J Deng; Stephen W Morton; Paula T Hammond
Journal:  Small       Date:  2014-04-24       Impact factor: 13.281

3.  Fluorogenic RNA nanoparticles for monitoring RNA folding and degradation in real time in living cells.

Authors:  Randall Reif; Farzin Haque; Peixuan Guo
Journal:  Nucleic Acid Ther       Date:  2012-10-31       Impact factor: 5.486

4.  The Use of Minimal RNA Toeholds to Trigger the Activation of Multiple Functionalities.

Authors:  Kirill A Afonin; Mathias Viard; Philip Tedbury; Eckart Bindewald; Lorena Parlea; Marshall Howington; Melissa Valdman; Alizah Johns-Boehme; Cara Brainerd; Eric O Freed; Bruce A Shapiro
Journal:  Nano Lett       Date:  2016-02-29       Impact factor: 11.189

5.  RNA nanoparticle distribution and clearance in the eye after subconjunctival injection with and without thermosensitive hydrogels.

Authors:  Zhanquan Shi; S Kevin Li; Ponwanit Charoenputtakun; Chia-Yang Liu; Daniel Jasinski; Peixuan Guo
Journal:  J Control Release       Date:  2017-11-21       Impact factor: 9.776

6.  Picomolar Fingerprinting of Nucleic Acid Nanoparticles Using Solid-State Nanopores.

Authors:  Mohammad Amin Alibakhshi; Justin R Halman; James Wilson; Aleksei Aksimentiev; Kirill A Afonin; Meni Wanunu
Journal:  ACS Nano       Date:  2017-09-11       Impact factor: 15.881

7.  Functional assays for specific targeting and delivery of RNA nanoparticles to brain tumor.

Authors:  Tae Jin Lee; Farzin Haque; Mario Vieweger; Ji Young Yoo; Balveen Kaur; Peixuan Guo; Carlo M Croce
Journal:  Methods Mol Biol       Date:  2015

8.  Ocular delivery of pRNA nanoparticles: distribution and clearance after subconjunctival injection.

Authors:  Liang Feng; S Kevin Li; Hongshan Liu; Chia-Yang Liu; Kathleen LaSance; Farzin Haque; Dan Shu; Peixuan Guo
Journal:  Pharm Res       Date:  2013-12-03       Impact factor: 4.200

Review 9.  Ultrastable pRNA hexameric ring gearing hexameric phi29 DNA-packaging motor by revolving without rotating and coiling.

Authors:  Chad Schwartz; Peixuan Guo
Journal:  Curr Opin Biotechnol       Date:  2013-05-14       Impact factor: 9.740

10.  Specific Delivery of MiRNA for High Efficient Inhibition of Prostate Cancer by RNA Nanotechnology.

Authors:  Daniel W Binzel; Yi Shu; Hui Li; Meiyan Sun; Qunshu Zhang; Dan Shu; Bin Guo; Peixuan Guo
Journal:  Mol Ther       Date:  2016-04-29       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.